Trials / Unknown
UnknownNCT04740996
Study of Pembrolizumab in the First Line Therapy for R/M HNSCC in China
A Prospective Registration Study of Pembrolizumab in the First Line Therapy for PD-L1 CPS≥20 Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma in China
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 30 (estimated)
- Sponsor
- Shi Yuankai · Unknown
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This trial is main evaluate the efficacy and safety of pembrolizumab in the first-line treatment of Chinese patients with recurrent or metastatic head and neck squamous cell carcinoma with PD-L1 CPS≥20.
Detailed description
This trial is a single-center, prospective phase II clinical study, which mainly evaluates the efficacy and safety of first-line treatment with pembrolizumab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma with PDL1 CPS≥20 in China.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pembrolizumab | Pembrolizumab (formerly lambrolizumab, brand name Keytruda) is a humanized antibody used in cancer immunotherapy. This includes to treat melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, and stomach cancer. |
Timeline
- Start date
- 2021-02-04
- Primary completion
- 2024-02-01
- Completion
- 2024-02-01
- First posted
- 2021-02-05
- Last updated
- 2022-02-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04740996. Inclusion in this directory is not an endorsement.